JP2002255837A - Aldose reductase inhibitor - Google Patents

Aldose reductase inhibitor

Info

Publication number
JP2002255837A
JP2002255837A JP2001056079A JP2001056079A JP2002255837A JP 2002255837 A JP2002255837 A JP 2002255837A JP 2001056079 A JP2001056079 A JP 2001056079A JP 2001056079 A JP2001056079 A JP 2001056079A JP 2002255837 A JP2002255837 A JP 2002255837A
Authority
JP
Japan
Prior art keywords
production example
aldose reductase
tea
reductase inhibitor
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001056079A
Other languages
Japanese (ja)
Inventor
Keiji Takagi
啓二 高木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikimoto Pharmaceutical Co Ltd
Original Assignee
Mikimoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikimoto Pharmaceutical Co Ltd filed Critical Mikimoto Pharmaceutical Co Ltd
Priority to JP2001056079A priority Critical patent/JP2002255837A/en
Publication of JP2002255837A publication Critical patent/JP2002255837A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a safe and effective aldose reductase inhibitor preventing several kinds of complications of diabetes. SOLUTION: This aldose reductase inhibitor is obtained by formulating the extract of one or more of the aboveground parts of Filipendula ulmaria, the flowers and stems of Ilex paraguarienesis and Arnica montana, the aboveground parts of Allium schoenoprasum, the leaves of Pimenta dioicalis, Rubus suavissims S. Lee and Psidium guayava, the aboveground parts of lagerstroemia speciosa and the flowers and stems of Tanacetum vulgare.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は糖尿病の各種の合併症を
防ぐアルドースレダクターゼ阻害剤に関する。
The present invention relates to aldose reductase inhibitors which prevent various complications of diabetes.

【0002】[0002]

【従来の技術】我が国では約600万人もの糖尿病患者
がおり、さらにその傾向がある人も含めればわが国の人
口の10%にも達し、国民病の規模になりつつある。糖
尿病には、インシュリン依存型とインシュリン非依存型
との2つのタイプがあり、日本人の患者のほとんどがイ
ンシュリン非依存性糖尿病である。しかし、糖尿病は各
種の合併症を引き起こすと言われている。
2. Description of the Related Art In Japan, there are about 6 million diabetic patients, including those who tend to have this tendency, reaching 10% of Japan's population, and the scale of national illness is increasing. There are two types of diabetes, insulin-dependent and non-insulin-dependent, and most Japanese patients have non-insulin-dependent diabetes. However, diabetes is said to cause various complications.

【0003】メドゥスイート(セイヨウナツユキソウ)
は学名Filipendula ulmariaでヨーロッパ、アジア原産
の植物で食用や胃酸過多症、胸焼けなどの薬用にも利用
されている。マテ茶は学名Ilex paraguarienesisで南
アメリカに分布し、古くよりマテ茶として飲用されてい
る。
[0003] Medu sweet (Natsuyuki snow)
The name Filipendula ulmaria is a plant native to Europe and Asia, and is used for food and for medicinal purposes such as hyperacidity and heartburn. Mate tea is distributed in South America under the scientific name Ilex paraguarienesis, and has been used as mate tea since ancient times.

【0004】アルニカ(セイヨウウサギギク)学名Arni
ca montana はアルプス、ヒマラヤ、ロッキ−等の高山
帯温暖地に産するキク科の多年草であり、古くから消炎
薬として欧州で使用されている。チャービル(アサツ
キ)学名Allium schoenoprasumといい、食用に用いら
れる。オールスパイス(ピメント)は学名Pimenta dio
icalisといい、中央アメリカ、メキシコ、西インド諸島
を原産とする植物でその種子は香辛料として広く用いら
れている。テン茶(甜茶)はお茶として広く飲用されて
いるが、最近はアレルギー性鼻炎、花粉症に有効として
利用されている。
[0004] Arnica
ca montana is a perennial plant of the Asteraceae family which is produced in alpine warm regions such as the Alps, Himalayas and Rockies, and has long been used in Europe as an anti-inflammatory. Chabir (Asatsuki) Scientific name is Allium schoenoprasum and is used for food. All Spice (Pimento) is scientific name Pimenta dio
Called icalis, a plant native to Central America, Mexico and the West Indies, its seeds are widely used as spices. Ten tea (tencha) is widely consumed as tea, but is recently used as effective for allergic rhinitis and hay fever.

【0005】グァバ学名Psidium guayava は、バンジ
ロウあるいは番石榴と呼ばれ、フトモモ科バンジロウ属
の植物で、学名をプジジウム グアヤバ エル(Psidium
guajaba L.)という。一般には、その実を生食、ジャ
ム、ジュース等で食する。分布は、原産は熱帯アメリカ
であるが、熱帯、亜熱帯の各地で広く栽培され、日本で
は九州南部で栽培され、琉球諸島では野生化している。
また、グアバは、薬として腸炎、赤痢、消化不良性下痢
に用いられており、葉はお茶の代用とされている。ま
た、本願出願人が出願した特開平5−246837号公
報では、グアバの葉の溶媒抽出物を化粧料として用いる
ことにより美白、肌荒れ防止等の利用が図られている。
[0005] The guava scientific name Psidium guayava is called a bunjirou or gypsophile, and is a plant belonging to the genus Bunjiro in the family Myrtaceae, and its scientific name is Psidium guayava.
guajaba L.). Generally, the berries are eaten raw, jam, juice, or the like. It is native to tropical America, but is widely cultivated in tropical and subtropical areas, cultivated in southern Kyushu in Japan, and wild in the Ryukyu Islands.
Guava is used as a drug for enteritis, dysentery, and indigestive diarrhea, and leaves are used as a substitute for tea. Further, in Japanese Patent Application Laid-Open No. 5-246837 filed by the applicant of the present application, use of a solvent extract of guava leaves as a cosmetic material is intended to use for whitening, prevention of rough skin, and the like.

【0006】オオバナサルスベリ学名lagerstroemia sp
eciosaは、ミソハギ科サルスベリ属の植物でインドに生
える半落葉高木である。このオオバナサルスベリの根
は、下痢に、樹皮、葉は下剤として利用されているタン
ジーは学名Tanacetum vulgareといい、広く食用にされ
ている。
[0006] Lagerstroemia sp.
eciosa is a semi-deciduous tree that grows in India and is a plant belonging to the genus Lagerstroemia in the family Sorrelidae. The roots of this sedge are used for diarrhea and the bark and leaves are used as laxatives. The tansy is called Tanacetum vulgare and is widely used for food.

【0007】[0007]

【従来の技術および発明が解決しようとする課題】イン
シュリン非依存的に、グルコースの取り込みを行う水晶
体、網膜、末梢神経などの組織では、糖尿病による高い
血糖値により細胞内グルコース濃度が上昇し、主経路の
解糖系で代謝しきれない過剰のグルコースは、細胞中の
アルドースレダクターゼによりソルビトールに変換され
る。ソルビトールは細胞膜電荷のために細胞外に出にく
く、さらにソルビトール脱水酵素(副経路のポリオール
経路上でフルクトースへの変換を促す)による処理速度
が遅いことなどから、ソルビトールが細胞内に蓄積さ
れ、細胞内浸透圧が上昇して細胞の膨化と細胞膜の変性
が起こり、結果としておきた細胞障害により、網膜症、
腎症、神経障害等の糖尿病合併症等の種々の糖尿病合併
症が発症すると考えられている。従来、糖尿病の治療薬
として、インシュリンや種々の血糖降下剤が用いるのみ
ならず、糖尿病合併症に関しても充分な注意が必要であ
るので、これに関与するアルドースレダクターゼの活性
を阻害する物質を配合することによってさらに有効な薬
品あるいは食品を得ることを目的とした。
2. Description of the Related Art In tissues such as the lens, the retina, and peripheral nerves that take up glucose independently of insulin, the intracellular glucose concentration increases due to a high blood glucose level due to diabetes. Excess glucose that cannot be metabolized in the glycolysis pathway of the pathway is converted to sorbitol by aldose reductase in cells. Sorbitol is difficult to get out of the cell due to cell membrane charge, and the processing speed by sorbitol dehydratase (which promotes the conversion of fructose into the alternative pathway into fructose) is slow. Increased internal osmotic pressure causes cell swelling and cell membrane degeneration, resulting in cell damage, retinopathy,
It is considered that various diabetic complications such as diabetic complications such as nephropathy and neuropathy occur. Conventionally, as a therapeutic agent for diabetes, not only insulin and various hypoglycemic agents are used, but also sufficient attention is required for diabetic complications. Thus, the purpose was to obtain a more effective drug or food.

【0008】[0008]

【課題を解決するための手段】本発明者らは安全で有効
なアルドースレダクターゼ阻害活性成分について種々検
討した結果、メドゥスイートの地上部、マテ茶、アルニ
カの花または茎、チャーブルの地上部、オールスパイ
ス、テン茶、グアバの葉、オオハナサルスベリの地上
部、タンジーの花または茎の1種以上の抽出物が高い阻
害活性を有することを見出し、本発明に到達した。
As a result of various studies on safe and effective aldose reductase-inhibiting active ingredients, the present inventors have found that the above-ground parts of Medu Sweet, yerba mate, flowers or stems of Arnica, the above-ground parts of charble, The inventors have found that one or more extracts of spices, marten tea, guava leaves, above-ground parts of the labaceae, tansy flowers or stems have high inhibitory activity, and reached the present invention.

【0009】これらの植物を水或いは水溶性有機溶媒或
いは、水溶性有機溶媒と水の混合物で抽出する。水溶性
有機溶媒はメタノール、エタノール、グリセリン、プロ
ピレングリコール、或いはこれらの混合物を用いること
ができる。熱を加えることも抽出速度が増すので必要に
よりこの工程を加える。
These plants are extracted with water or a water-soluble organic solvent or a mixture of a water-soluble organic solvent and water. As the water-soluble organic solvent, methanol, ethanol, glycerin, propylene glycol, or a mixture thereof can be used. This step may be added as needed, as heating also increases the extraction rate.

【0010】このように抽出したメドゥスイートの地上
部、マテ茶、アルニカの花または茎、チャーブルの地上
部、オールスパイス、テン茶、グアバの葉、オオハナサ
ルスベリの地上部、タンジーの花または茎の抽出物を必
要により溶媒を留去して、薬や食品にさまざまな剤型に
配合することができる。例えば、丸薬、錠剤、シロッ
プ、粉末、健康茶の形態にすることができる。
[0010] The above-ground parts of the medu suite extracted above, mate tea, arnica flowers or stems, above-ground parts of charbles, allspice, marble tea, guava leaves, above-ground parts of Ohanasrassberg, tansy flowers or stems The solvent can be distilled off from the extract as necessary, and the extract can be incorporated into medicines and foods in various dosage forms. For example, it can be in the form of pills, tablets, syrups, powders, and healthy tea.

【0011】また、本発明は糖尿病の合併症予防のため
用いられるものなので、当然、スルホニル尿素剤、スル
ホンアミド薬、ビグアナイド薬、ボグリボース、アカル
ボースなどの糖尿病予防薬やヤーコン、ギムネバシルベ
スタ、シベリア人参、高麗人参、プロポリス、ビージャ
サーラなどの糖尿病予防を予防する食品との併用するこ
とが好ましく、この薬或いは食品にも同時に血糖降下剤
などの糖尿病予防に有効な成分を配合することが望まし
い。また、所謂,食事療法も併用することが望ましい。
Since the present invention is used for the prevention of complications of diabetes, it should be understood that diabetes preventives such as sulfonylureas, sulfonamides, biguanides, voglibose and acarbose and yacon, gymneva sylvester, siberian ginseng, etc. , Ginseng, propolis, villasala and the like, which are preferably used in combination with foods for preventing diabetes, and this medicine or foods are desirably combined with a component effective for preventing diabetes, such as a hypoglycemic agent. It is also desirable to use a so-called diet therapy together.

【0012】[0012]

【実施例】以下に製造例、実施例によって、更に具体的
に説明するが、本発明は、この製造例、実施例によっ
て、限定されるものでないことは云うまでもない。
EXAMPLES The present invention will be described more specifically with reference to the following production examples and examples. However, it goes without saying that the present invention is not limited to these production examples and examples.

【0013】〔製造例1−1〕メドゥスイートの地上部
(乾燥品)10gを細砕したのち、50%エタノール水
溶液300mlを加えて時々撹拌しつつ5日間放置した。
これを濾過後、エバポレートした後、凍結乾燥した。た
後、凍結乾燥した。
[Production Example 1-1] 10 g of the above-ground portion (dried product) of Medu Sweet was pulverized, and then 300 ml of a 50% ethanol aqueous solution was added, and the mixture was left for 5 days with occasional stirring.
After filtration, evaporation and freeze-drying. After freeze-drying.

【0014】〔製造例1−2〕メドゥスイートの地上部
(乾燥品)10gを細砕したのち、精製水300mlを加
えて時々撹拌しつつ5時間、加熱した。これを放冷した
のち、濾過し、凍結乾燥した。
[Production Example 1-2] 10 g of the above-ground part (dried product) of Medu Sweet was pulverized, and then 300 ml of purified water was added thereto and heated for 5 hours with occasional stirring. After allowing to cool, it was filtered and freeze-dried.

【0015】〔製造例2−1〕マテ茶(乾燥品)10g
を細砕したのち、エタノール300mlを加えて時々撹拌
しつつ5日間放置した。これを濾過後、エバポレートし
た後、凍結乾燥した。
[Production Example 2-1] 10 g of mate tea (dried product)
After grinding, 300 ml of ethanol was added, and the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.

【0016】〔製造例2−2〕マテ茶(乾燥品)10g
を細砕したのち、50%エタノール水溶液300mlを加
えて時々撹拌しつつ5日間放置した。これを濾過後、エ
バポレートした後、凍結乾燥した。
[Production Example 2-2] 10 g of mate tea (dried product)
After grinding, 300 ml of a 50% aqueous ethanol solution was added, and the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.

【0017】〔製造例2−3〕マテ茶(乾燥品)10g
を細砕したのち、精製水300mlを加えて時々撹拌しつ
つ5時間、加熱した。これを放冷したのち、濾過し、凍
結乾燥した。
[Production Example 2-3] Mate tea (dry product) 10 g
After pulverizing, 300 ml of purified water was added, and the mixture was heated for 5 hours with occasional stirring. After allowing to cool, it was filtered and freeze-dried.

【0018】〔製造例3−1〕アルニカの花または茎
(乾燥品)10gを細砕したのち、50%エタノール水
溶液300mlを加えて時々撹拌しつつ5日間放置した。
これを濾過後、エバポレートした後、凍結乾燥した。
[Production Example 3-1] Arnica flower or stem (dry product) (10 g) was pulverized, and then 300 ml of a 50% ethanol aqueous solution was added.
After filtration, evaporation and freeze-drying.

【0019】〔製造例4−1〕チャーブルの地上部(乾
燥品)10gを細砕したのち、50%エタノール水溶液
300mlを加えて時々撹拌しつつ5日間放置した。これ
を濾過後、エバポレートした後、凍結乾燥した。
[Preparation Example 4-1] 10 g of the above-ground portion (dried product) of the charble was crushed, and 300 ml of a 50% aqueous ethanol solution was added thereto. After filtration, evaporation and freeze-drying.

【0020】〔製造例4−2〕チャーブルの地上部(乾
燥品)10gを細砕したのち、精製水300mlを加えて
時々撹拌しつつ5時間、加熱した。これを放冷したの
ち、濾過し、凍結乾燥した。
[Production Example 4-2] 10 g of the above-ground portion (dried product) of the charble was pulverized, and then 300 ml of purified water was added thereto, followed by heating for 5 hours with occasional stirring. After allowing to cool, it was filtered and freeze-dried.

【0021】〔製造例5−1〕オールスパイス(乾燥
品)10gを細砕したのち、50%エタノール水溶液3
00mlを加えて時々撹拌しつつ5日間放置した。これを
濾過後、エバポレートした後、凍結乾燥した。
[Production Example 5-1] After crushing 10 g of allspice (dry product), a 50% aqueous ethanol solution 3
After adding 00 ml, the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.

【0022】〔製造例5−2〕オールスパイス(乾燥
品)10gを細砕したのち、精製水300mlを加えて時
々撹拌しつつ5時間、加熱した。これを放冷したのち、
濾過し、凍結乾燥した。
[Production Example 5-2] 10 g of all-spice (dry product) was pulverized, and then 300 ml of purified water was added thereto, followed by heating for 5 hours with occasional stirring. After letting it cool,
Filtered and lyophilized.

【0023】〔製造例6−1〕テン茶(乾燥品)10g
を細砕したのち、50%エタノール水溶液300mlを加
えて時々撹拌しつつ5日間放置した。これを濾過後、エ
バポレートした後、凍結乾燥した。
[Production Example 6-1] 10 g of ten tea (dried product)
After grinding, 300 ml of a 50% aqueous ethanol solution was added, and the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.

【0024】〔製造例7−1〕グアバの葉(乾燥品)1
0gを細砕したのち、50%エタノール水溶液300ml
を加えて時々撹拌しつつ5日間放置した。これを濾過
後、エバポレートした後、凍結乾燥した。
[Production Example 7-1] Guava leaf (dried product) 1
After grinding 0 g, 300 ml of 50% ethanol aqueous solution
Was added and left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying.

【0025】〔製造例8−1〕オオハナサルスベリの地
上部(乾燥品)10gを細砕したのち、50%エタノー
ル水溶液300mlを加えて時々撹拌しつつ5日間放置し
た。これを濾過後、エバポレートした後、凍結乾燥し
た。
[Production Example 8-1] 10 g of the above-ground portion (dried product) of Prunus brassicae was ground, and 300 ml of a 50% aqueous ethanol solution was added thereto. After filtration, evaporation and freeze-drying.

【0026】〔製造例9−1〕タンジーの花または茎
(乾燥品)10gを細砕したのち、50%エタノール水
溶液300mlを加えて時々撹拌しつつ5日間放置した。
これを濾過後、エバポレートした後、凍結乾燥した。
[Production Example 9-1] 10 g of a tansy flower or stem (dried product) was pulverized, and 300 ml of a 50% aqueous ethanol solution was added thereto. The mixture was allowed to stand for 5 days with occasional stirring.
After filtration, evaporation and freeze-drying.

【0027】実施例−1 健康食品(錠剤) A:ヤーコン 20.0% B:プロポリス 10.0% C:ビタミンE 5.0% D:製造例1−1 25.0% E:デキストリン 25.0% F:結晶セルロース 22.5% G:ショ糖脂肪酸エステル 2.0% H:デンプン 0.5% 製法はA〜Fの各成分を秤量し、流動層造粒機でHを結
合剤溶液として顆粒化する。その後Gを加え均一に混合
し打錠機で錠剤とする。
Example-1 Health food (tablets) A: 20.0% for yacon B: 10.0% for propolis C: 5.0% for vitamin E D: Production example 1-1 25.0% E: dextrin 25. 0% F: crystalline cellulose 22.5% G: sucrose fatty acid ester 2.0% H: starch 0.5% The manufacturing method weighs each of the components A to F and converts H into a binder solution using a fluidized bed granulator. Granulate as Thereafter, G is added and mixed uniformly, and made into tablets by a tableting machine.

【0028】実施例−2 健康食品(顆粒) A:製造例1−2 20.0% B:製造例2−1 20.0% C:製造例3−1 10.0% D:エリスリトール 30.0% E:結晶セルロース 18.0% F:ショ糖脂肪酸エステル 1.5% G:デンプン 0.5% 製法はA〜Eの各成分を秤量し、流動層造粒機でGを結
合剤溶液として顆粒化する。その後Fを加え均一に混合
し顆粒とする。
Example 2 Healthy Food (Granules) A: Production Example 1-2 20.0% B: Production Example 2-1 20.0% C: Production Example 3-1 10.0% D: Erythritol 0% E: microcrystalline cellulose 18.0% F: sucrose fatty acid ester 1.5% G: starch 0.5% In the manufacturing method, each component of A to E is weighed, and G is used as a binder solution in a fluidized bed granulator. Granulate as Thereafter, F is added and mixed uniformly to obtain granules.

【0029】実施例−3 スープ(粉末スープ) A:高麗人参 20.0% B:製造例2−3 10.0% C:製造例4−1 5.0% D:製造例5−1 5.0% E:大豆タンパク 15.0% F:粉末油脂 13.0% G:ブイヨン 11.0% H:食塩 6.0% I:増粘剤(グァーガム) 5.0% J:乳タンパク 5.0% K:調味料(アミノ酸等) 3.0% L:香料 2.0% 製法はA〜Lの各成分を秤量し均一に混合して粉末スー
プとする。
Example-3 Soup (powder soup) A: Ginseng 20.0% B: Production Example 2-3 10.0% C: Production Example 4-1 5.0% D: Production Example 5-1-5 0.0% E: Soy protein 15.0% F: Powdered oil 13.0% G: Bouillon 11.0% H: Salt 6.0% I: Thickener (guar gum) 5.0% J: Milk protein 5 0.0% K: Seasoning (amino acids, etc.) 3.0% L: Flavor 2.0% In the manufacturing method, each component of A to L is weighed and uniformly mixed to obtain a powdered soup.

【0030】実施例−4 お茶(粉末タイプ) A:製造例2−3 10.0% B:製造例4−2 10.0% C:製造例6−1 10.0% D:バナバ茶 25.0% E:ハト麦 25.0% F:紅茶 20.0% 製法はA〜Fの各成分を秤量し均一に混合して粉末とす
る。
Example-4 Tea (powder type) A: Production Example 2-3 10.0% B: Production Example 4-2 10.0% C: Production Example 6-1 10.0% D: Banaba tea 25 0.0% E: Pigeon wheat 25.0% F: Black tea 20.0% In the manufacturing method, each component of A to F is weighed and uniformly mixed to obtain a powder.

【0031】実施例−5 健康食品(錠剤) A:ギムネバシルベスタ 20.0% B:シベリア人参 10.0% C:ビタミンE 5.0% D:製造例7−1 15.0% D:製造例8−1 10.0% E:デキストリン 25.0% F:結晶セルロース 22.5% G:ショ糖脂肪酸エステル 2.0% H:デンプン 0.5% 製法はA〜Fの各成分を秤量し、流動層造粒機でHを結
合剤溶液として顆粒化する。その後Gを加え均一に混合
し打錠機で錠剤とする。
Example-5 Health Food (Tablets) A: Gymneva Sylvester 20.0% B: Siberian Ginseng 10.0% C: Vitamin E 5.0% D: Production Example 7-1 15.0% D: Production Example 8-1 10.0% E: dextrin 25.0% F: crystalline cellulose 22.5% G: sucrose fatty acid ester 2.0% H: starch 0.5% The production method uses each component of A to F. Weigh and granulate H as binder solution in fluid bed granulator. Thereafter, G is added and mixed uniformly, and made into tablets by a tableting machine.

【0032】実施例−6 健康食品(顆粒) A:製造例9−1 20.0% B:製造例4−2 20.0% C:製造例7−1 10.0% D:エリスリトール 30.0% E:結晶セルロース 18.0% F:ショ糖脂肪酸エステル 1.5% G:デンプン 0.5% 製法はA〜Eの各成分を秤量し、流動層造粒機でGを結
合剤溶液として顆粒化する。その後Fを加え均一に混合
し顆粒とする。
Example-6 Healthy Food (Granules) A: Production Example 9-1 20.0% B: Production Example 4-2 20.0% C: Production Example 7-1 10.0% D: Erythritol 0% E: microcrystalline cellulose 18.0% F: sucrose fatty acid ester 1.5% G: starch 0.5% In the manufacturing method, each component of A to E is weighed, and G is used as a binder solution in a fluidized bed granulator. Granulate as Thereafter, F is added and mixed uniformly to obtain granules.

【0033】アルドースレダクターゼ阻害試験 試験方法を以下に示す。水1.5ml、0.175%メルカ
プトエタノールを含む500mMリン酸カリウムバッフ
ァー(pH6.0)0.6ml、1Mグルコース水溶液0.
6ml、サンプル溶液0.05ml、2mMのNADPH水
溶液(pH7.0)0.15ml、0.035%メルカプト
エタノールを含む10mMリン酸ナトリウムバッファー
(pH7.0)3.6mlに1.3unit/mlのアルドースレ
ダクターゼ0.4mlを加えた溶液0.1mlを以上の順で混
合する。酵素添加と同時に時間を計る。37℃でインキ
ュベートしながら5分間340nmの吸光度を測定す
る。水を対照としたときの吸光度が経時的に低下するの
で、サンプルの1分間の吸光度低下の抑制率を酵素阻害
率とした。
Aldose reductase inhibition test The test method is described below. 1.5 ml of water, 0.6 ml of 500 mM potassium phosphate buffer (pH 6.0) containing 0.175% mercaptoethanol, and 0.1 ml of 1 M aqueous glucose solution.
1.3 unit / ml aldose in 6 ml, 0.05 ml of sample solution, 0.15 ml of 2 mM aqueous NADPH solution (pH 7.0), and 3.6 ml of 10 mM sodium phosphate buffer (pH 7.0) containing 0.035% mercaptoethanol. 0.1 ml of a solution to which 0.4 ml of reductase has been added is mixed in the above order. Time the addition of the enzyme. Measure the absorbance at 340 nm for 5 minutes while incubating at 37 ° C. Since the absorbance of water as a control decreases with time, the inhibition rate of the absorbance decrease of the sample for 1 minute was defined as the enzyme inhibition rate.

【0034】結果を表に示す。 The results are shown in the table.

【0035】[0035]

【効果】メドゥスイートの地上部、マテ茶、アルニカの
花または茎、チャーブルの地上部、オールスパイス、テ
ン茶、グアバの葉、オオハナサルスベリの地上部、タン
ジーの花または茎の抽出物の1種以上の抽出物を配合し
たアルドースレダクターゼ阻害剤は今まで食用とされた
植物で安全性が高く、アルドースレダクターゼを阻害
し、糖尿病の各種の合併症を防ぐことができる。
[Effect] One of the above-ground parts of Medu Sweet, Yerba Mate, Arnica flower or stem, above-ground part of Chaburu, allspice, marbled tea, guava leaf, above-ground part of Ohanasasuruberi, Tanji flower or stem extract The aldose reductase inhibitor containing the above extract has high safety in plants that have been edible so far, inhibits aldose reductase, and can prevent various complications of diabetes.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) C12N 9/99 C12N 9/99 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) C12N 9/99 C12N 9/99

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】メドゥスイートの地上部、マテ茶、アルニ
カの花または茎、チャーブルの地上部、オールスパイ
ス、テン茶、グアバの葉、オオハナサルスベリの地上
部、タンジーの花または茎の1種以上の抽出物を配合し
たアルドースレダクターゼ阻害剤
1. An above-ground part of a medu suite, a mate tea, an arnica flower or stem, an above-ground part of a chabble, allspice, marten tea, guava leaves, an above-ground part of a giant crab, or a tansy flower or stem. Aldose reductase inhibitor containing an extract of
JP2001056079A 2001-03-01 2001-03-01 Aldose reductase inhibitor Pending JP2002255837A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001056079A JP2002255837A (en) 2001-03-01 2001-03-01 Aldose reductase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001056079A JP2002255837A (en) 2001-03-01 2001-03-01 Aldose reductase inhibitor

Publications (1)

Publication Number Publication Date
JP2002255837A true JP2002255837A (en) 2002-09-11

Family

ID=18916157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001056079A Pending JP2002255837A (en) 2001-03-01 2001-03-01 Aldose reductase inhibitor

Country Status (1)

Country Link
JP (1) JP2002255837A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004161644A (en) * 2002-11-12 2004-06-10 Fuji Sangyo Kk Pancreatic lipase inhibitor and food product containing the inhibitor
US7247324B1 (en) 2006-01-06 2007-07-24 Amerilabtechnologies, Inc. Method of using guava extract and composition including guava extract
WO2008038705A1 (en) * 2006-09-29 2008-04-03 Kobayashi Pharmaceutical Co., Ltd. Glycation inhibitor
EP1843734A4 (en) * 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions and methods for enhancing cognitive function
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2011093418A1 (en) * 2010-01-27 2011-08-04 株式会社 資生堂 Agent for promoting differentiation of adipocyte precursor cells
US8313784B2 (en) 2006-01-06 2012-11-20 Amerilab Technologies, Inc. Method of using guava extract

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103742A (en) * 1998-09-30 2000-04-11 Mikimoto Pharmaceut Co Ltd Amylase inhibitor
JP2000169384A (en) * 1998-12-09 2000-06-20 Yuusu Techno Corporation:Kk Blood glucose level increase inhibitor or hypoglycemic agent
JP2001039880A (en) * 1999-05-25 2001-02-13 Yuusu Techno Corporation:Kk Liquid composition for transpiratory use for inhibiting blood glucose level rise, and transpirator for the composition and use of the transpirator
JP2002012547A (en) * 2000-06-28 2002-01-15 Ito En Ltd Saccharide decomposition-inhibiting agent, insulin secretion-inhibiting agent, and health beverage or food
JP2002205949A (en) * 2001-01-04 2002-07-23 Yuusu Techno Corporation:Kk Method for ameliorating dysbolism and composition therefor
JP2002241299A (en) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd Maillard reaction recovering agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103742A (en) * 1998-09-30 2000-04-11 Mikimoto Pharmaceut Co Ltd Amylase inhibitor
JP2000169384A (en) * 1998-12-09 2000-06-20 Yuusu Techno Corporation:Kk Blood glucose level increase inhibitor or hypoglycemic agent
JP2001039880A (en) * 1999-05-25 2001-02-13 Yuusu Techno Corporation:Kk Liquid composition for transpiratory use for inhibiting blood glucose level rise, and transpirator for the composition and use of the transpirator
JP2002012547A (en) * 2000-06-28 2002-01-15 Ito En Ltd Saccharide decomposition-inhibiting agent, insulin secretion-inhibiting agent, and health beverage or food
JP2002205949A (en) * 2001-01-04 2002-07-23 Yuusu Techno Corporation:Kk Method for ameliorating dysbolism and composition therefor
JP2002241299A (en) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd Maillard reaction recovering agent

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
JP2004161644A (en) * 2002-11-12 2004-06-10 Fuji Sangyo Kk Pancreatic lipase inhibitor and food product containing the inhibitor
EP1843734A4 (en) * 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7247324B1 (en) 2006-01-06 2007-07-24 Amerilabtechnologies, Inc. Method of using guava extract and composition including guava extract
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US8313784B2 (en) 2006-01-06 2012-11-20 Amerilab Technologies, Inc. Method of using guava extract
WO2008038705A1 (en) * 2006-09-29 2008-04-03 Kobayashi Pharmaceutical Co., Ltd. Glycation inhibitor
WO2011093418A1 (en) * 2010-01-27 2011-08-04 株式会社 資生堂 Agent for promoting differentiation of adipocyte precursor cells

Similar Documents

Publication Publication Date Title
JP5568806B2 (en) Diabetes or diabetes complication preventive
KR20070111623A (en) Pharmaceutical composition for treating or preventing diabetic complication containing an extract of chinese herb as an effective ingredient
KR20200004942A (en) Composition for Liver Protection Containing Hub Extract and Beverage Thereof
JP2006045212A (en) Oral composition containing specific quinic acid derivative
KR101849301B1 (en) Composition for treatment and prevention of dry eye syndrome comprising Aucuba japonica extract
KR101292837B1 (en) Composition for skin wrinkle improvement comprising extracts of Junglans mandshurica MAXIM as an active ingredient
KR20160007728A (en) Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same
JP2002255837A (en) Aldose reductase inhibitor
KR101788253B1 (en) Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic
JP2006045213A (en) Oral composition containing specific quinic acid derivative
Rana et al. The various pharmacological activity of Adansonia digitata
KR100986975B1 (en) Pharmaceutical composition for the treatment of atopic dermatitis
KR101829810B1 (en) Fermented composition containing both forage barley and medicinal herbs extract material, and a preparation method thereof
CN103948021B (en) A kind of Flos Chrysanthemi eyesight-improving health care function granule and production method thereof
KR100768830B1 (en) Extract of echinosophora koreensis removing hangover and having anti-oxidant activity
JP4818549B2 (en) Aldose reductase inhibitor
Roy et al. Herbs Used In Peptic Ulcer: A Review.
KR100642801B1 (en) Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same
JP7120660B2 (en) Blood sugar level increase inhibitor and antiflatulent agent
JP7203394B1 (en) oral composition
KR100758267B1 (en) Compositions effective for removing hangover, which contain natural plant extracts
KR102330844B1 (en) Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis
KR102039623B1 (en) Milk thistle granule composition for protecting hepatocyte and manufacturing method thereof
KR101989006B1 (en) Peanut Sprouts granule for relieving hangover and manufacturing method thereof
KR101911628B1 (en) The method of preparing a counteractive using medicinal stuff plant

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110419

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130924

A072 Dismissal of procedure

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20140121